Biogen GmbH

Company number 0462.285.469

Track this competitor Create a free account to be notified when it wins a contract.

Contracts won: 3
Amount won alone: €2,115,713 excl. VAT
Shared contracts: 2 (multi-supplier framework agreements)
Period: 3 July 2024 – 24 September 2026

Its main clients

DAK-Gesundheit · 2 contracts
Association iris-Achats · 1 contract

Where and what

Supplies · 3

Brussels-Capital · 1

Its contracts coming to an end

So many opportunities to take over these contracts when they are re-tendered.

Planned end	Contract	Current holder	Amount
26 June 2028 re-tender around December 2027	Spécialités pharmaceutiques à base d'infliximab IV Association iris-Achats	Biogen NV/SA 2 bids received	€2,115,713

Contracts won

Date	Contract	Buyer	Amount
24/09/2026	Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2024 - 31.08.2026	DAK-Gesundheit	€1 shared by 18
03/09/2026	Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Natalizumab (ausschl. in der Dafo. Injektionslösung, ATC L04AA23 für die Zeit 01.09.24 - 31.08.26	DAK-Gesundheit	€1 shared by 4
03/07/2024	Spécialités pharmaceutiques à base d'infliximab IV	Association iris-Achats	€2,115,713

Source: contract award notices published on TED (Publications Office of the European Union), above the EU thresholds. Contracts published only in Belgium are not included yet.